MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

25.33 +1.27 (+5.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tango Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
From Tango Therapeutics Sub, Inc
Via GlobeNewswire
News headline image
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets ↗
This precision oncology developer reported a notable insider sale during a period of robust share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge ↗
This clinical-stage biotech focused on targeted cancer therapies reported a notable insider sale. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗
Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships. 
Via The Motley Fool
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
A Peek at Tango Therapeutics's Future Earnings ↗
 
Via Benzinga
News headline image
Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗
This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For August 5, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 12, 2025 ↗
 
Via Benzinga
News headline image
Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗
This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗
This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader
The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood... 
Via MarketMinute
Topics Intellectual Property
News headline image
TANGO THERAPEUTICS INC (NASDAQ:TNGX) Posts Strong Q3 Earnings Beat Amid Mixed Market Reaction ↗
Tango Therapeutics (TNGX) reported a strong Q3, beating revenue and EPS estimates. Despite the earnings beat, the stock saw mixed market reaction. 
Via Chartmill
Topics Earnings
News headline image
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? ↗
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement ↗
Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers. 
Via Benzinga
News headline image
Wondering what's happening in today's pre-market session? ↗
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy ↗
CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Tango (TNGX) Q2 Revenue Drops 52% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Tango Therapeutics Inc (NASDAQ:TNGX) Reports Q2 2025 Earnings: Revenue Misses, EPS Meets Expectations Amid Clinical Progress ↗
Tango Therapeutics (TNGX) reported Q2 2025 revenue below estimates but met EPS expectations, causing a 2.4% pre-market dip. Clinical progress in oncology trials remains a key focus. 
Via Chartmill
News headline image
5 Biotech Stocks with Highly Anticipated Pending Results ↗
Via Stocktwits
Topics Intellectual Property
News headline image
Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
What's going on in today's session ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story